Klotho Neurosciences, a biotechnology company, has recently embarked on the manufacturing and development of its gene therapy candidate, KLTO-202, utilizing the cutting-edge platform technology of AAVnerGene Inc. This collaboration marks a significant milestone for Klotho, leveraging AAVnerGene’s expertise in adeno-associated viruses (AAV) manufacturing and targeted delivery systems. The innovative approach involves harnessing a human gene and protein derived from the “anti-aging” Klotho gene, showcasing a promising avenue for disease-modifying cell and gene therapies.
Dr. Joseph Sinkule, the CEO of Klotho, expressed enthusiasm about the transformative potential of AAVnerGene’s technology in streamlining AAV vector manufacturing. By employing AAVnerGene’s ‘AAVone’ platform technology and engineered HEK293 cell line, Klotho aims to enhance the production efficiency of AAV particles carrying the Klotho gene. This optimized process results in higher concentrations of gene-containing AAV particles with reduced impurities, offering a faster and more cost-effective alternative to traditional manufacturing methods. The strategic partnership with AAVnerGene holds the promise of accelerating the clinical advancement of Klotho’s product candidates, ensuring heightened efficacy and purity levels.
One of the key hurdles in AAV-based gene therapies is the liver’s tendency to attract AAVs, triggering inflammatory responses that pose severe risks to patients. AAVnerGene’s ‘ATHENA’ platform has been instrumental in developing tissue-specific AAVs, enabling precise targeting of gene therapies to specific tissues. By incorporating Klotho’s tissue-specific promoters into the gene therapy products, the collaboration aims to mitigate potential safety concerns associated with AAVs homing in on the liver, enhancing the overall therapeutic profile of the KLTO gene therapy candidates.
Traditionally, the field of gene therapy has relied on the cumbersome ‘triple transfection’ method, involving the insertion of three DNA plasmids into HEK293 cells to produce AAV vectors. This intricate process demands meticulous optimization and extended timelines for completion. AAVnerGene’s pioneering ‘AAVone’ packaging system revolutionizes this approach by consolidating the packaging process into a single-plasmid system. The streamlined method significantly boosts production efficiency, simplifies operations, reduces impurities, and slashes development timelines and costs, marking a paradigm shift in gene therapy manufacturing practices.
Klotho Neurosciences stands at the forefront of biogenetics, dedicated to advancing innovative cell and gene therapies for neurodegenerative and age-related disorders. By leveraging the patented form of the human Klotho gene and novel delivery systems, the company aims to revolutionize the treatment landscape for conditions like ALS, Alzheimer’s disease, and Parkinson’s disease. The strategic collaboration with AAVnerGene underscores Klotho’s commitment to harnessing state-of-the-art technologies to drive therapeutic innovation and improve patient outcomes.
Key Takeaways:
– The partnership between Klotho Neurosciences and AAVnerGene heralds a new era in gene therapy manufacturing, leveraging advanced technologies for enhanced production efficiency and therapeutic efficacy.
– AAVnerGene’s ‘ATHENA’ platform offers targeted delivery solutions, mitigating safety concerns associated with AAV-induced inflammatory responses and optimizing tissue-specific gene therapy applications.
– The transition from traditional ‘triple transfection’ methods to AAVnerGene’s ‘AAVone’ packaging system signifies a substantial leap in streamlining gene therapy manufacturing processes, paving the way for accelerated clinical development and cost-effective production.
– Klotho Neurosciences’ focus on innovative cell and gene therapies underscores a commitment to addressing unmet medical needs in neurodegenerative and age-related disorders, positioning the company at the forefront of therapeutic advancements.
Tags: gene therapy, biotech, transfection
Read more on pharmabiz.com